Antonino Grassadonia

Author

Also Known As

A GRASSADONIA, A Grassadonia, A. Grassadonia, ANTONINO GRASSADONIA, Antonino Grassadonia, Antonino Grassadonia, Grassadonia, A, Grassadonia, A., Grassadonia,Antonino

138

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

University of Chieti-Pescara Istituti di Ricovero e Cura a Carattere Scientifico Ospedale SS. Annunziata Sapienza University of Rome Ospedale di Belcolle

About

Antonino Grassadonia is an author at University of Chieti-Pescara specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	911
2	Health Sciences	4	4	290
3	Cell Biology	4	4	91
4	Natural Sciences	1	1	26
5	Biochemistry	1	1	29

Antonino Grassadonia

Publications

Citations

H-Index

Page 1

	Year	Citations
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study Alessio Cortellini, Sebastiano Buti, Daniele Santini, The Oncologist ImmunologyImmunoeditingPathologyAnti-programmed Death-1 ImmunotherapyImmunotherapy	2019	214
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients Alessio Cortellini, Rita Chiari, Biagio Ricciuti, Clinical Lung Cancer Cancer ImmunosurveillanceAnti-pd1 ImmunotherapyImmunodeficienciesImmunologyClinical Trials	2019	174
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients Vincenzo Graziano, Antonino Grassadonia, Laura Iezzi, The Breast	2019	170
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy Alessio Cortellini, Massimo Di Maïo, Olga Nigro, Journal for ImmunoTherapy of Cancer	2021	132
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, The Lancet Oncology Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer	2018	86
FPSE-HPLC-DAD method for the quantification of anticancer drugs in human whole blood, plasma, and urine Marcello Locatelli, Nicola Tinari, Antonino Grassadonia, Journal of Chromatography B Fpse-hplc-dad MethodHuman Whole BloodPreclinical Drug EvaluationMedicineChemical Pathology	2018	76
The flavonoid quercetin inhibits thyroid-restricted genes expression and thyroid function Cesidio Giuliani, Ines Bucci, Serena Di Santo, Food and Chemical Toxicology Flavonoid QuercetinMedicineThyroid DiseaseThyroid HormoneEndocrinology	2014	73
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience Patrizia Vici, Laura Pizzuti, Andrea Michelotti, Oncotarget	2017	68
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score Antonio Galvano, Marta Peri, Aurelia Guarini, Therapeutic Advances in Medical Oncology	2020	58
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation Davide Brocco, Paola Lanuti, Pasquale Simeone, Journal of Oncology	2019	54

Page 1